Full Text View
Tabular View
No Study Results Posted
Related Studies
Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment
This study is ongoing, but not recruiting participants.
Study NCT00162097.   Last updated on May 6, 2009.
Information provided by Bristol-Myers Squibb
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Hepatic Impairment
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Infection
Liver Diseases
More general conditions related to this trial
Digestive System Diseases
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Additional drug interventions recognized in this trial
Efavirenz
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Bristol-Myers Squibb


U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services